SciSparc Ltd. (SPRC) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorders, has announced a non-binding letter of intent to sell its majority stake in MitoCareX Bio for a potential total of $8 million, reflecting a 47% increase in valuation since its initial investment. The transaction, which includes milestone-based increments to the consideration, is aimed at enhancing shareholder value and aligns with SciSparc’s strategic focus on investment and partnership opportunities.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.
